Biotech ETF Market Vectors (BBH) 114.43 $BBH
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 320.75 (-2.72), BBH: 114.43 (-0.81), AMGN: 160.25 (-0.10), CELGZ: 3.24 (-0.04)
Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Oct 30, 8:00AM CDT
After some solid biotech stock earnings, these top ranked health care ETFs could be intriguing buys.
BIIB: 320.75 (-2.72), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81), AMGN: 160.25 (-0.10)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Biotech ETF and PowerShares Dynamic Biotechnology & Genome Portfolio- GENOME
PR Newswire - Fri Oct 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), SPDR S&P Biotech ETF (AMEX:XBI-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and PowerShares Dynamic Biotechnology & Genome Portfolio - GENOME (AMEX
BE-Free Report).
FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81)
The Complete Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 11:09AM CDT
Biotech sector appears to be back on track with fundamentals remaining attractive.
PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81), IBB: 290.14 (-3.18)
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), BBH: 114.43 (-0.81), IBB: 290.14 (-3.18)
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 320.75 (-2.72), PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 320.75 (-2.72), PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
Last Week's ETF Highlights: MLP and Biotech Funds Soar, Volatility Sinks - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 20, 7:00AM CDT
Which ETFs led the market higher and lower last week?
ZROZ: 109.39 (+1.34), KMI: 38.75 (+0.22), VXX: 29.03 (-0.42), FCG: 15.60 (+0.86), BBH: 114.43 (-0.81), MLPI: 43.92 (+0.93), CVOL: 1.13 (+0.02)
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
GILD: 106.45 (-0.49), PJP: 66.42 (-1.50), AMGN: 160.25 (-0.10), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81), CELG: 106.45 (-0.69)
The Fed's Valuation Concerns Put These Growth ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 17, 9:00AM CDT
Thanks to Yellen and her comments, these high growth ETFs could be in focus.
SOCL: 19.14 (+0.01), VB: 116.08 (+0.24), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81), IWM: 116.71 (+0.18)
The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEXBE-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), BBH: 114.43 (-0.81)
Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
Biotech HOLDRs Trust Shares Down 10.5% Since SmarTrend's Sell Call (BBH)
Comtex SmarTrend(R) - Mon Mar 31, 9:27AM CDT
SmarTrend identified a Downtrend for Biotech HOLDRs Trust (AMEX:BBH) on March 7th, 2014 at $100.08. In approximately 3 weeks, Biotech HOLDRs Trust has returned 10.52% as of today's recent price of $89.55.
BBH: 114.43 (-0.81)
The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF
PR Newswire - Fri Oct 31, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), Celgene (Nasdaq:CELG-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report).
BIIB: 320.75 (-2.72), BBH: 114.43 (-0.81), AMGN: 160.25 (-0.10), CELGZ: 3.24 (-0.04)
Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Oct 30, 8:00AM CDT
After some solid biotech stock earnings, these top ranked health care ETFs could be intriguing buys.
BIIB: 320.75 (-2.72), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81), AMGN: 160.25 (-0.10)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, Market Vectors Biotech ETF and PowerShares Dynamic Biotechnology & Genome Portfolio- GENOME
PR Newswire - Fri Oct 03, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), SPDR S&P Biotech ETF (AMEX:XBI-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report) and PowerShares Dynamic Biotechnology & Genome Portfolio - GENOME (AMEX
BE-Free Report). FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81)
The Complete Guide to Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 11:09AM CDT
Biotech sector appears to be back on track with fundamentals remaining attractive.
PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), BBH: 114.43 (-0.81), IBB: 290.14 (-3.18)
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), BBH: 114.43 (-0.81), IBB: 290.14 (-3.18)
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 320.75 (-2.72), PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
BIIB: 320.75 (-2.72), PBE: 48.56 (-0.41), GILD: 106.45 (-0.49), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
Last Week's ETF Highlights: MLP and Biotech Funds Soar, Volatility Sinks - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 20, 7:00AM CDT
Which ETFs led the market higher and lower last week?
ZROZ: 109.39 (+1.34), KMI: 38.75 (+0.22), VXX: 29.03 (-0.42), FCG: 15.60 (+0.86), BBH: 114.43 (-0.81), MLPI: 43.92 (+0.93), CVOL: 1.13 (+0.02)
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
GILD: 106.45 (-0.49), PJP: 66.42 (-1.50), AMGN: 160.25 (-0.10), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81), CELG: 106.45 (-0.69)
The Fed's Valuation Concerns Put These Growth ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 17, 9:00AM CDT
Thanks to Yellen and her comments, these high growth ETFs could be in focus.
SOCL: 19.14 (+0.01), VB: 116.08 (+0.24), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81), IWM: 116.71 (+0.18)
The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX
BE-Free Report) and SPDR S&P Biotech ETF (AMEX:XBI-Free Report). PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), BBH: 114.43 (-0.81)
Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
PBE: 48.56 (-0.41), FBT: 97.23 (-1.31), XBI: 167.72 (-1.28), IBB: 290.14 (-3.18), BBH: 114.43 (-0.81)
Biotech HOLDRs Trust Shares Down 10.5% Since SmarTrend's Sell Call (BBH)
Comtex SmarTrend(R) - Mon Mar 31, 9:27AM CDT
SmarTrend identified a Downtrend for Biotech HOLDRs Trust (AMEX:BBH) on March 7th, 2014 at $100.08. In approximately 3 weeks, Biotech HOLDRs Trust has returned 10.52% as of today's recent price of $89.55.
BBH: 114.43 (-0.81)
